According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca‘s grant share as of February 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibitors of complement factor d for treating disorders
A recently granted patent (Publication Number: US11926617B2) discloses a method for treating disorders mediated by complement factor D. The method involves administering a compound of a specific formula to a host in need of treatment. The compound can be selected from various formulas specified in the claims, with the host typically being a human individual.
The disorders that can be treated using this method include atypical hemolytic uremic syndrome, dense deposit disease, geographic atrophy, IgA nephropathy, lupus nephritis, myasthenia gravis, neuromyelitis optica, reduced glomerular filtration rate, renovascular disorder, and sickle cell disease. By targeting complement factor D, the method aims to address a range of conditions affecting different parts of the body, from the kidneys to the nervous system. This patent provides a novel approach to treating these disorders and offers potential therapeutic options for patients in need.
To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies